Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway.
about
Type 2 diabetes and cognitive impairment: linking mechanismsPathophysiology of diabetic retinopathyDiabetic kidney disease: from physiology to therapeuticsRosiglitazone via upregulation of Akt/eNOS pathways attenuates dysfunction of endothelial progenitor cells, induced by advanced glycation end products.Therapeutic interventions and oxidative stress in diabetesPreventive effect of taurine on experimental type II diabetic nephropathy.Aldolase B knockdown prevents high glucose-induced methylglyoxal overproduction and cellular dysfunction in endothelial cells.Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics.Elevated Glucose Levels Promote Contractile and Cytoskeletal Gene Expression in Vascular Smooth Muscle via Rho/Protein Kinase C and Actin PolymerizationImproved diabetes control in the elderly delays global cognitive declineCan advanced glycation end product inhibitors modulate more than one pathway to enhance renoprotection in diabetes?Uremic Toxicity of Advanced Glycation End Products in CKD.Mechanisms linking diabetes mellitus to the development of atherosclerosis: a role for endoplasmic reticulum stress and glycogen synthase kinase-3.Tandem inhibition of PKC in Diαβetic nephropathy: it takes two to tango?A glimpse of various pathogenetic mechanisms of diabetic nephropathy.Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complicatDiabetic threesome (hyperglycaemia, renal function and nutrition) and advanced glycation end products: evidence for the multiple-hit agent?The AGE/RAGE axis in diabetes-accelerated atherosclerosis.Recent insights into diabetic renal injury from the db/db mouse model of type 2 diabetic nephropathy.New approaches to the treatment of nephropathy in diabetes.What are new avenues for renal protection, in addition to RAAS inhibition?Current therapeutic interventions in the glycation pathway: evidence from clinical studies.The renal endothelium in diabetic nephropathy.Role of protein kinase C in podocytes and development of glomerular damage in diabetic nephropathy.Oxidation as an important factor of protein damage: Implications for Maillard reaction.New molecular insights in diabetic nephropathy.A synopsis on aging-Theories, mechanisms and future prospects.Inhibitory effect of gallic acid on advanced glycation end products induced up-regulation of inflammatory cytokines and matrix proteins in H9C2 (2-1) cells.Vasculopathy in the setting of cardiorenal syndrome: roles of protein-bound uremic toxins.Dicarbonyls and Advanced Glycation End-Products in the Development of Diabetic Complications and Targets for Intervention.Antioxidants ameliorate the expression of vascular endothelial growth factor mediated by protein kinase C in diabetic podocytes.Body weight control by a high-carbohydrate/low-fat diet slows the progression of diabetic kidney damage in an obese, hypertensive, type 2 diabetic rat model.Effects of atorvastatin on progression of diabetic nephropathy and local RAGE and soluble RAGE expressions in rats.Renoprotective effect of Coccinia indica fruits and leaves in experimentally induced diabetic rats.Alagebrium attenuates acute methylglyoxal-induced glucose intolerance in Sprague-Dawley rats.Oxidative stress induces renal failure: A review of possible molecular pathways.Inhibition of miR-25 aggravates diabetic peripheral neuropathy.Deciphering Non-coding RNAs in Cardiovascular Health and Disease.
P2860
Q26822993-707329FD-FFBB-473E-928F-C60AE15718ECQ26865897-6AC9C93C-E374-48BB-B789-57F2AF6651E1Q27021392-77F7EB57-E5C0-4AB8-8E7F-66601DD1D0CCQ33595290-5439205C-27F8-4A0F-9608-90D44A297DAAQ33870395-204986BE-84C5-4D18-A075-C4722A8D62C4Q34364305-1740A541-ACEA-47B3-801F-5A0C036DC504Q34387932-80D853C1-08E1-497E-8E54-3F0D5EF9357CQ35809946-E89438CA-E899-4D82-853C-4C1E1A432D64Q35873096-D638C655-9F5D-43AB-AABD-914616783530Q35895265-79EE746F-4828-42FE-9740-3291A070AC8BQ36204022-1069EBA2-FB78-4BC0-81C8-2BA07EAA351EQ36514906-F82D7744-94FE-4475-AB5C-A8D4BB8F4A65Q36538348-083CF436-F049-4B60-9C8D-FAE0F3E84FD6Q36720570-9FC1D96B-27F3-4ACB-8992-4D708DB20802Q36979205-1C180926-2292-4A47-B28E-83D45052F1F0Q37054987-ED7ADAE2-8FBD-4C7C-9782-B58545C65E5EQ37072018-4BFE668D-BDD5-491D-BBB2-E8AF58F16497Q37091107-C8726A35-39D8-41FA-925C-14DE391FFB3DQ37819453-F3F34F4C-5966-4DD6-A34E-3A7A83D6EC51Q37899907-AED770C1-84CF-4546-8A50-D8F45962DD8FQ37980677-5DB8A358-B037-4EEF-90A8-E769100D40D9Q38070906-A5D0FDC3-D298-45EE-8246-E6684DFF01C2Q38087656-5069F0A0-3C6B-4A0C-AFC1-805CA231F40CQ38270180-6DD5CC27-2049-422E-9A3A-991073B06071Q38473579-1BF425F9-D2B9-4AEB-88B3-CDF27A2C712EQ38694219-49EB5B0A-7484-4DE7-A718-E54EF668E2E9Q38847549-FCC66EC4-2E35-4063-B41D-8E2D9D010537Q39092599-AF01A557-CF18-4852-8F5F-3D9B6A3C7810Q39243739-79867F10-5BB2-4165-AE6C-366A37E22EFAQ39285661-008A035C-8DF0-4193-95D4-4277564E98EAQ40315191-5103FA91-E794-4C69-ACFB-875D8FC17886Q41828830-93E3FD5A-05FF-48C3-BE8D-2043307F6540Q42537047-1DE95DE7-B4DD-45EF-98AF-B8921E728E3DQ42645738-78B14455-0F41-4B14-9D40-C11BC71266EDQ42914144-6A17C5F2-8F7C-47E1-94EB-72F5C5395F49Q47642456-DF0947FF-51D4-4479-B492-55E3E57DD001Q54976817-760677F8-FC2F-485A-B863-EDD26F152AD8Q55668859-4C85870C-761F-4941-9777-C2398C43223F
P2860
Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Attenuation of extracellular m ...... ase C-alpha-dependent pathway.
@en
Attenuation of extracellular m ...... ase C-alpha-dependent pathway.
@nl
type
label
Attenuation of extracellular m ...... ase C-alpha-dependent pathway.
@en
Attenuation of extracellular m ...... ase C-alpha-dependent pathway.
@nl
prefLabel
Attenuation of extracellular m ...... ase C-alpha-dependent pathway.
@en
Attenuation of extracellular m ...... ase C-alpha-dependent pathway.
@nl
P2093
P50
P1433
P1476
Attenuation of extracellular m ...... nase C-alpha-dependent pathway
@en
P2093
Bishoy Rizkalla
Carsten Lindschau
Geoffrey Boner
Mark E Cooper
Matthias Meier
Vicki Thallas-Bonke
P304
P356
10.2337/DIABETES.53.11.2921
P407
P577
2004-11-01T00:00:00Z